CEL-SCI Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CVM | EDSA | CELU | BCTX | IMMP | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 24.27M | 29.32M | 26.25M | 27.86M | 21.74M | 131.36M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.2 | — | -1.4 | -8.2 | -0.9 | -1.3 |
| Price/book | 2.2 | 52.9 | -0.7 | 1.7 | 0.5 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −79.22% | +27.65% | −55.60% | −70.55% | −91.38% | −42.95% |
| Today | −2.13% | −4.82% | −1.02% | +5.98% | −1.50% | +5.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CVM news ›Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 2.1% – Here’s What Happened
Posted by Tristan Rich on Nov 5th, 2026 Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report) shares fell 2.1% on Wednesday. The company traded as low as $1.38 and last traded at $1.38. Approximately 27,787 shares changed hands during…
CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational…
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
These criteria define the target population in which neoadjuvant Multikine (administered over 3 weeks prior to surgery) demonstrated its strongest survival effect. These selection criteria will be applied prospectively in the upcoming U.S.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com2
- proactiveinvestors.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.